Effect of Switching from Conventional Continuous Subcutaneous Insulin Infusion to Sensor Augmented Pump Therapy on Glycemic Profile in Japanese Patients with Type 1 Diabetes

Overview

Journal Diabetol Int

Specialty Endocrinology

Date 2019 Jan 4

PMID 30603368

Citations 7

Authors

Atsuko Matsuoka

Yushi Hirota

Shin Urai

Tetsushi Hamaguchi

Takehito Takeuchi

Hiroshi Miura

Natsu Suematsu

Anna So

Tomoaki Nakamura

Hisako Komada

Yuko Okada

Kazuhiko Sakaguchi

Wataru Ogawa

Affiliations

Soon will be listed here.

Abstract

Aims: Evidence suggests that sensor augmented pump (SAP) therapy is superior to conventional continuous subcutaneous insulin infusion (CSII) for achieving glycemic control in patients with type 1 diabetes. However, the clinical benefit of SAP therapy in East Asians has not yet been demonstrated.

Methods: The effect of switching from conventional CSII to SAP therapy on glycemic profile was examined in 18 Japanese patients with type 1 diabetes. The glycemic profile of the patients was determined by retrospective continuous glucose monitoring (CGM) within 1 month before the treatment switch, whereas that at 6 and 12 months after the switch was evaluated with the CGM function of the SAP device. Hemoglobin A1c levels were also measured before and after the switch to SAP therapy.

Results: The duration of hypoglycemia was significantly decreased at both 6 and 12 months after the change in treatment (6.6 ± 4.5, 3.2 ± 4.1, and 3.0 ± 2.8 min/h for before and 6 and 12 months, respectively), as was the HbA1c level at 12 months (7.8 ± 1.0 and 7.4 ± 0.9%, respectively). The duration of hyperglycemia did not differ between before and after the treatment switch. The decline in HbA1c level at 12 months after the switch to SAP was negatively correlated with age.

Conclusion: Switching from conventional CSII to SAP therapy was associated with a decrease in both the duration of hypoglycemia and the level of HbA1c in Japanese patients with type 1 diabetes.

Citing Articles

Elevated urinary albumin predicts increased time in range after initiation of SGLT2 inhibitors in individuals with type 1 diabetes on sensor-augmented pump therapy.

Suganuma Y, Ishiguro M, Ohno T, Nishimura R Diabetol Int. 2024; 15(4):806-813.

PMID: 39469555 PMC: 11512966. DOI: 10.1007/s13340-024-00743-4.

Advantages of sensor-augmented insulin pump therapy for pregnant women with type 1 diabetes mellitus.

Imafuku H, Tanimura K, Masuko N, Tomimoto M, Shi Y, Uchida A J Diabetes Investig. 2023; 14(12):1383-1390.

PMID: 37706627 PMC: 10690839. DOI: 10.1111/jdi.14075.

A sensor augmented pump may improve awareness of hypoglycemia and quality of life in Japanese patients with type 1 diabetes mellitus.

Takagi S, Miura J, Shimura K, Hoshina S, Tsuchida Y, Takita M Diabetol Int. 2022; 13(1):280-287.

PMID: 35059264 PMC: 8733106. DOI: 10.1007/s13340-021-00538-x.

Type 1 diabetes woman with repeated miscarriages successfully gave birth after introducing an insulin pump with a predictive low glucose suspend feature.

Honoki H, Yagi K, Tsuda S, Wada T, Enkaku A, Nakagawa-Yokoyama M Diabetol Int. 2021; 12(3):324-329.

PMID: 34150440 PMC: 8172753. DOI: 10.1007/s13340-020-00489-9.

Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas.

Kesavadev J, Saboo B, Krishna M, Krishnan G Diabetes Ther. 2020; 11(6):1251-1269.

PMID: 32410184 PMC: 7261311. DOI: 10.1007/s13300-020-00831-z.

References

Cryer P, Davis S, Shamoon H . Hypoglycemia in diabetes. Diabetes Care. 2003; 26(6):1902-12. DOI: 10.2337/diacare.26.6.1902. View

Norgaard K, Scaramuzza A, Bratina N, Lalic N, Jarosz-Chobot P, Kocsis G . Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study. Diabetes Technol Ther. 2013; 15(4):273-80. PMC: 3696941. DOI: 10.1089/dia.2012.0288. View

Beck R, Buckingham B, Miller K, Wolpert H, Xing D, Block J . Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2009; 32(11):1947-53. PMC: 2768196. DOI: 10.2337/dc09-0889. View

Schutt M, Kern W, Krause U, Busch P, Dapp A, Grziwotz R . Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes. 2006; 114(7):384-8. DOI: 10.1055/s-2006-924152. View

Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J . Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011; 34(4):795-800. PMC: 3064030. DOI: 10.2337/dc10-1989. View

Beck R, Hirsch I, Laffel L, Tamborlane W, Bode B, Buckingham B . The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009; 32(8):1378-83. PMC: 2713649. DOI: 10.2337/dc09-0108. View

Nishimura R, Izumi K, Hayashino Y, Origasa H, Noda M, Ueki K . A large-scale observational study to investigate the current status of diabetes complications and their prevention in Japan: research outline and baseline data for type 1 diabetes-JDCP study 2. Diabetol Int. 2019; 7(1):4-11. PMC: 6224906. DOI: 10.1007/s13340-015-0248-5. View

Signal M, Thomas F, Shaw G, Chase J . Complexity of continuous glucose monitoring data in critically ill patients: continuous glucose monitoring devices, sensor locations, and detrended fluctuation analysis methods. J Diabetes Sci Technol. 2013; 7(6):1492-506. PMC: 3876327. DOI: 10.1177/193229681300700609. View

Thordarson H, Sovik O . Dead in bed syndrome in young diabetic patients in Norway. Diabet Med. 1995; 12(9):782-7. DOI: 10.1111/j.1464-5491.1995.tb02080.x. View

10.

Mochizuki M, Kikuchi T, Urakami T, Kikuchi N, Kawamura T, Yokomichi H . Improvement in glycemic control through changes in insulin regimens: findings from a Japanese cohort of children and adolescents with type 1 diabetes. Pediatr Diabetes. 2016; 18(6):435-442. DOI: 10.1111/pedi.12409. View

11.

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

12.

Battelino T, Conget I, Olsen B, Schutz-Fuhrmann I, Hommel E, Hoogma R . The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012; 55(12):3155-62. PMC: 3483098. DOI: 10.1007/s00125-012-2708-9. View

13.

Buse J, Dailey G, Ahmann A, Bergenstal R, Green J, Peoples T . Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. Diabetes Technol Ther. 2011; 13(6):601-6. PMC: 3101919. DOI: 10.1089/dia.2010.0225. View

14.

Nathan D, Zinman B, Cleary P, Backlund J, Genuth S, Miller R . Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience.... Arch Intern Med. 2009; 169(14):1307-16. PMC: 2866072. DOI: 10.1001/archinternmed.2009.193. View

15.

Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S . Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2005; 29(1):44-50. DOI: 10.2337/diacare.29.01.06.dc05-1686. View

16.

Karter A, Ferrara A, Darbinian J, Ackerson L, Selby J . Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. Diabetes Care. 2000; 23(4):477-83. DOI: 10.2337/diacare.23.4.477. View

17.

Murata T, Tsuzaki K, Yoshioka F, Okada H, Kishi J, Yamada K . The relationship between the frequency of self-monitoring of blood glucose and glycemic control in patients with type 1 diabetes mellitus on continuous subcutaneous insulin infusion or on multiple daily injections. J Diabetes Investig. 2015; 6(6):687-91. PMC: 4627546. DOI: 10.1111/jdi.12362. View

18.

Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H . Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care. 2009; 32(12):2245-50. PMC: 2782985. DOI: 10.2337/dc09-0750. View

19.

Hansen M, Pedersen-Bjergaard U, Heller S, Wallace T, Rasmussen A, Jorgensen H . Frequency and motives of blood glucose self-monitoring in type 1 diabetes. Diabetes Res Clin Pract. 2009; 85(2):183-8. DOI: 10.1016/j.diabres.2009.04.022. View

20.

OConnell M, Donath S, ONeal D, Colman P, Ambler G, Jones T . Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia. 2009; 52(7):1250-7. DOI: 10.1007/s00125-009-1365-0. View